Zantac 75 Efferdose could challenge Alka-Seltzer as leading effervescent stomach remedy.
This article was originally published in The Tan Sheet
Executive Summary
ZANTAC 75 EFFERDOSE COULD CHALLENGE ALKA-SELTZER as the top effervescent OTC stomach remedy, following FDA's recent approval of Glaxo Wellcome's NDA for the effervescent tablet version of 75 mg ranitidine. Zantac 75 Efferdose is the first approved nonprescription effervescent H2 antagonist. FDA cleared the product for OTC marketing on Feb. 26, the day of the agency's original user fee goal ("The Tan Sheet" March 2, p. 1). Warner- Lambert, which markets Zantac 75, also will market the effervescent tablets.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning